Under the terms of the agreement, Intrexon will receive an upfront payment of $115 million. For the first two targets of interest selected by Merck Serono, Intrexon will receive research funding and is eligible to receive up to $826 million development, regulatory and commercial milestones, as well as tiered royalties on product sales. In addition, Intrexon is also eligible to receive further payments upon achievement of certain technology development milestones.
EXACTLY! MAUs could = 2...who cares if revenues continue to double every year.
lower the share count to hide a falling EPS #. Without it EPS decreases year over year. WAKE UP! Management is swindling the entire invesotr base while lining their own pockets with inflated salaries and stock based compensation programs. This all ends under $10 and by that time management will be rich 10X over. PITIFUL!